JP2013534408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534408A5 JP2013534408A5 JP2013509591A JP2013509591A JP2013534408A5 JP 2013534408 A5 JP2013534408 A5 JP 2013534408A5 JP 2013509591 A JP2013509591 A JP 2013509591A JP 2013509591 A JP2013509591 A JP 2013509591A JP 2013534408 A5 JP2013534408 A5 JP 2013534408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- represented
- light chain
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1053712A FR2959994B1 (fr) | 2010-05-12 | 2010-05-12 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
| FR1053712 | 2010-05-12 | ||
| PCT/FR2011/050745 WO2011141653A1 (fr) | 2010-05-12 | 2011-04-01 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016146495A Division JP6435295B2 (ja) | 2010-05-12 | 2016-07-26 | ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534408A JP2013534408A (ja) | 2013-09-05 |
| JP2013534408A5 true JP2013534408A5 (https=) | 2014-05-15 |
| JP6043998B2 JP6043998B2 (ja) | 2016-12-14 |
Family
ID=43413855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509591A Active JP6043998B2 (ja) | 2010-05-12 | 2011-04-01 | ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント |
| JP2016146495A Active JP6435295B2 (ja) | 2010-05-12 | 2016-07-26 | ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016146495A Active JP6435295B2 (ja) | 2010-05-12 | 2016-07-26 | ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9012607B2 (https=) |
| EP (1) | EP2569333B1 (https=) |
| JP (2) | JP6043998B2 (https=) |
| CN (1) | CN103119059B (https=) |
| AR (1) | AR081159A1 (https=) |
| BR (1) | BR112012028859B1 (https=) |
| CA (1) | CA2798336C (https=) |
| DK (1) | DK2569333T3 (https=) |
| ES (1) | ES2661080T3 (https=) |
| FR (1) | FR2959994B1 (https=) |
| WO (1) | WO2011141653A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013016576A1 (en) | 2011-07-26 | 2013-01-31 | United Parcel Service Of American, Inc. | Systems and methods for managing fault codes |
| FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| US10509035B2 (en) * | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
| WO2017079303A1 (en) * | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
| FR3060394B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
| KR20200014276A (ko) | 2017-04-14 | 2020-02-10 | 가마맵스 파마 | 암을 예방 또는 치료하기 위한 amhrii-결합 화합물 |
| US20230227566A1 (en) * | 2017-04-14 | 2023-07-20 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
| CN111108123A (zh) * | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | 癌症相关的免疫抑制抑制剂 |
| EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
| EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
| WO2021155295A1 (en) * | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002216864A1 (en) * | 2000-12-21 | 2002-07-01 | Mcgill University | Conjugates of antibodies and anticancer drugs |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005005615A2 (en) * | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
| CA2631327C (en) * | 2005-12-02 | 2015-10-13 | Genentech, Inc. | Her2 binding polypeptides and uses thereof |
| WO2007117657A2 (en) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| WO2007134037A2 (en) * | 2006-05-15 | 2007-11-22 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| EP1918304A1 (en) * | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
-
2010
- 2010-05-12 FR FR1053712A patent/FR2959994B1/fr active Active
-
2011
- 2011-04-01 JP JP2013509591A patent/JP6043998B2/ja active Active
- 2011-04-01 EP EP11718450.7A patent/EP2569333B1/fr active Active
- 2011-04-01 BR BR112012028859-8A patent/BR112012028859B1/pt active IP Right Grant
- 2011-04-01 DK DK11718450.7T patent/DK2569333T3/en active
- 2011-04-01 US US13/697,575 patent/US9012607B2/en active Active
- 2011-04-01 ES ES11718450.7T patent/ES2661080T3/es active Active
- 2011-04-01 AR ARP110101115A patent/AR081159A1/es active IP Right Grant
- 2011-04-01 CA CA2798336A patent/CA2798336C/fr active Active
- 2011-04-01 CN CN201180032211.8A patent/CN103119059B/zh active Active
- 2011-04-01 WO PCT/FR2011/050745 patent/WO2011141653A1/fr not_active Ceased
-
2015
- 2015-03-16 US US14/658,785 patent/US9637544B2/en active Active
-
2016
- 2016-07-26 JP JP2016146495A patent/JP6435295B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534408A5 (https=) | ||
| Suriben et al. | Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice | |
| AU2016300208B2 (en) | Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer | |
| AU2021273240B2 (en) | Anti-tigit antibody and preparation method and application thereof | |
| AU2017384471B2 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
| US20210388049A1 (en) | Novel Rationally Designed Protein Compositions | |
| CN117120477A (zh) | 针对密蛋白18a2和cd3的双特异性抗体及其应用 | |
| TW201942136A (zh) | Her3抗原結合分子 | |
| TW201134487A (en) | Therapeutic DLL4 binding proteins | |
| JP2014511179A5 (https=) | ||
| JP2020530272A (ja) | Ｒｏｒ１抗体 | |
| JP2022506719A (ja) | タウ認識抗体 | |
| CN107001480B (zh) | 用于人c-maf的结合成员 | |
| Casaletto et al. | MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM | |
| EP3830122A1 (en) | Dosing regimen for bcma-cd3 bispecific antibodies | |
| AU2017239038B2 (en) | Administration of an anti-LGR5 monoclonal antibody | |
| CN114796497A (zh) | 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物 | |
| TW202409096A (zh) | 結合ｄｌｌ３和ｃｄ３的異多聚體 | |
| TW202043271A (zh) | 重組抗人程序性細胞死亡蛋白1抗體及其應用 | |
| EP4590706A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| US20250122303A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| TW202328196A (zh) | 使用vista抗原結合分子的癌症之治療及預防 | |
| WO2022095934A1 (zh) | 抗Siglec-15抗体及其在制备药物中的应用 | |
| WO2023046979A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| US11191823B2 (en) | Compositions and methods for treating arenavirus infection |